AUSTIN, Texas--(BUSINESS WIRE)--Aeglea BioTherapeutics, Inc., a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the appointment of Anthony Quinn, M.B Ch.B, Ph.D., FRCP to its Board of Directors. Dr. Quinn most recently served as executive vice president, chief medical officer and head of research & development at Synageva Biopharma Corp. until its acquisition by Alexion Pharmaceuticals in 2015.
“Anthony’s proven leadership and extensive experience in drug development, including recent success in the rare disease space, make him a strong addition to our Board,” said David G. Lowe, Ph.D., co-founder, president and chief executive officer of Aeglea. “I look forward to working with him as we further the strategic objectives of Aeglea, including the continued development of our lead product candidate, AEB1102, for inborn errors of metabolism and oncology.”
During his tenure at Synageva, Dr. Quinn played a key role in securing the European and U.S. approvals of Kanuma™ for Lysosomal Acid Lipase Deficiency, and in building the company’s research and development organization and rare disease drug pipeline. Prior to his role at Synageva, he served as worldwide head of clinical research and exploratory development for inflammatory diseases at Roche. Previously, Dr. Quinn was a professor of dermatology at Barts and The London School of Medicine. He received his Bachelor of Medical Science and his M.B Ch.B from the University of Dundee, and a Ph.D. from the University of Newcastle upon Tyne.
About Aeglea BioTherapeutics
Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company’s engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of certain cancers on specific amino acids. In addition to the ongoing Phase 1 clinical trial in solid tumors with its lead product candidate AEB1102, Aeglea expects to begin trials in 2016 of AEB1102 in patients with Arginase I deficiency and in cancer patients with hematological malignancies. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.
For more information, visit http://aegleabio.com.